|drug829||Patients admitted to Intensive Care Unit with SARS-CoV2 Wiki||1.00|
|drug649||Lopinavir/ritonavir treatment Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.06|
|D018352||Coronavirus Infections NIH||0.05|
There is one clinical trial.
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from these pneumonia patients and developed a real-time reverse transcription PCR (real time RT-PCR) diagnostic assay. In view of the fact that there is currently no effective antiviral therapy, the prevention or treatment of lung injury caused by COVID-19 can be an alternative target for current treatment. Xiyanping injection has anti-inflammatory and immune regulation effects. This study is a Randomized, Parallel Controlled Clinical Study to treat patients with COVID-19 infection.
Description: The time from study drug use to complete fever reduction and cough recovery is measured in hours.Measure: Clinical recovery time Time: Up to Day 28